| 000 | 01323na a2200229 4500 | ||
|---|---|---|---|
| 003 | PC1560 | ||
| 005 | 20180417112018.0 | ||
| 008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_9432 _aManso Sánchez, Luis _eOncología Médica |
||
| 245 | 0 | 0 |
_aSafety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. _h[artículo] |
| 260 |
_bAnnals of oncology: official journal of the European Society for Medical Oncology, _c2013 |
||
| 300 | _a24(1):109-16. | ||
| 500 | _aFormato Vancouver: Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013 Jan;24(1):109-16. | ||
| 501 | _aPMID: 22967996 | ||
| 504 | _aContiene 43 referencias | ||
| 520 | _aBACKGROUND: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer. | ||
| 710 |
_9303 _aServicio de Oncología Médica |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1560.pdf _ySolicitar documento |
||
| 942 |
_n0 _2ddc _cART |
||
| 999 |
_c1560 _d1560 |
||